x min read

BPS initiates coverage on Cellceutix Corp (OTCMKTS:CTIX)

BPS initiates coverage on Cellceutix Corp (OTCMKTS:CTIX)
Written by
Aaron Smith
Published on
October 27, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

On 17th October’14, BrilliantPennyStocks.com initiated coverage on CTIX. The stock moved up by 19.43% since the coverage was initiated.

Clinical stage drug maker Cellceutix Corp (OTCMKTS:CTIX) announced encouraging top-line data and corresponding results from its ongoing Phase 2b ABSSSI Trial last week. The results were positive, since the test determined that a single dose of target drug Brilacidin was able to generate effects, which were comparable to a 7-day treatment course of drug Daptomycin. The target drug is being designed to treat various forms of “Acute Bacterial Skin and Skin Structure Infections.”

End Goal Objectives

The clinical trial consisted of comparing “three dosing regimens” between Cellceutix Corp (OTCMKTS:CTIX) developed drug candidate

Brilacidin and approved drugdaptomycin for the treatment of skin ailments. The clinical trials had commenced in February of this year. It had registered nearly 215 patients into the program. The end goal of the phase-2 tests was to determine if there was at least a 20% dip in the “area of ABSSSI lesion, relative to baseline” after 48 to 72 hour have elapsed since the first dose of test drug administration.

End Goal Objectives Of Phase 2b Tests Met

The end goals thus listed out are said to be consistent with the latest guidelines laid out by the Food and Drug Administration with respect to ABSSSI drug development and approval process. Post the analysis of the phase2b test data; the drug maker has reported that all the three dosage regimens had successfully reached their “primary end point goals.”

Road Ahead

On the back of the positive reading of the data from its phase 2b trials, Cellceutix Corp (OTCMKTS:CTIX) has indicated its resolve to initiate the pivotal Phase-3 trials for the drug candidate in 2015. The drug maker hopes to beat its rivals in developing drug to treat skin disease by using novel antibiotics, known as defensin-mimetics. The drug maker has also indicated that it is working on developing “other anti-infective drugs” using the same “defensin-mimetics” platform.

About BrilliantPennyStocks

BSP provides sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. BPS provides alerts to investors and traders on stocks that could potentially breakout. To obtain text message stock alerts service, text the word Avauncer to 95577 from your cell phone. Additionally, BPS provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure: BrilliantPennyStocks is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://brilliantpennystocks.com/disclaimer/ for complete risks and disclosures.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.